GR
GRCE.US Grace Therapeutics, Inc.
- Market cap
- USD 38.1M
- P/E
- -
- P/B
- 0.79x
- ROE
- -64.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is GRCE.US undervalued?
Graham numberThe Graham number of Grace Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Grace Therapeutics, Inc. fundamental analysis
No fundamental analysis for Grace Therapeutics, Inc. yet.
Grace Therapeutics, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Grace Therapeutics, Inc.
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to enhance neurological symptoms of Ataxia-Telangiectasia (A-T); and GTX-101, a topical bio adhesive film-forming bupivacaine spray for the…
Full company profileGrace Therapeutics, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Grace Therapeutics, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | - | - | 309K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -2.57M | -2.68M | -3.12M | - | 189K | 0.00 | -124K | -11.0K | -7.00K | -7.00K | - |
| Operating Income | -10.5M | -15.3M | -34.4M | -48.8M | -25.9M | -19.5M | -70.5M | -17.4M | -23.8M | -11.1M | -36.2M |
| EBITDA | -7.95M | -14.3M | -36.8M | -47.4M | -15.7M | -19.2M | -24.6M | -15.4M | -23.7M | -11.1M | -35.9M |
| Net Income | -10.6M | -16.7M | -39.4M | -51.0M | -31.1M | -12.3M | -57.4M | -17.4M | -13.6M | -7.79M | -35.8M |
| EPS | -46 | -46 | -35 | -29 | -13 | -2.00 | -7.72 | -1.83 | -1.13 | -0.47 | -1.78 |
| Balance Sheet | |||||||||||
| Total Assets | 25.5M | 17.8M | 36.9M | 32.3M | 78.5M | 129M | 79.1M | 73.3M | 72.0M | 66.7M | 57.7M |
| Total Liabilities | 3.76M | 11.4M | 25.9M | 13.9M | 8.54M | 20.4M | 11.2M | 11.6M | 5.38M | 2.76M | 2.22M |
| Shareholders' Equity | 21.7M | 6.37M | 11.0M | 18.4M | 69.9M | 108M | 68.0M | 61.7M | 66.6M | 63.9M | 55.5M |
| Cash & Short-term Investments | 9.78M | 6.37M | 25.8M | 20.1M | 76.3M | 43.7M | 27.9M | 23.0M | 22.1M | 17.0M | 21.3M |
| Total Debt | 1.41M | 1.25M | 1.36M | 208K | 108K | 295K | 485K | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -6.94M | -9.69M | -24.8M | -32.4M | -18.0M | -17.2M | -15.9M | -12.3M | -14.9M | -8.87M | -10.0M |
| Capital Expenditure | 2.57M | 352K | 534K | 451K | 86.7K | 0.00 | 17.0K | 22.0K | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -9.51M | -10.0M | -25.3M | -32.9M | -18.1M | -17.2M | -15.9M | -12.4M | -14.9M | -8.87M | -10.0M |
| Ratios | |||||||||||
| ROE | -48.6% | -261.5% | -356.4% | -277.5% | -44.4% | -11.3% | -84.4% | -28.2% | -20.5% | -12.2% | -64.6% |
| ROA | -41.4% | -93.7% | -106.7% | -157.8% | -39.6% | -9.5% | -72.5% | -23.8% | -18.9% | -11.7% | -62.1% |
| Net Profit Margin | - | - | - | - | -10,039.8% | - | - | - | - | - | - |
| Debt to Equity | 0.06x | 0.20x | 0.12x | 0.01x | 0.00x | 0.00x | 0.01x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Grace Therapeutics, Inc. dividends
Grace Therapeutics, Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 1:6 on Jul 10, 2023.
Who owns Grace Therapeutics, Inc.
- Insiders 18.68%
- Institutions 33.05%
- Public & others 48.28%
- Shares outstanding 21.0M
- Free float 13.3M
Top funds holding GRCE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 400K | 2.46% | 0.00% | Sep 2026 |
| iShares Micro-Cap ETF | 38.1K | 0.23% | 0.00% | Oct 2026 |
| Fidelity Nasdaq Composite Index | 3.21K | 0.02% | 0.00% | Aug 2026 |
| 1290 VT Micro Cap K | 2.35K | 0.01% | 0.00% | Sep 2026 |
Top institutions holding GRCE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| HPM Partners LLC | 849K | 5.22% | 0.00% | Jun 2026 |
| Eversept Partners, LP | 773K | 4.75% | +2.15% | Jun 2026 |
| Bank of America Corp | 495K | 3.04% | -0.01% | Jun 2026 |
| Vanguard Capital Management, LLC | 412K | 2.53% | +2.50% | Jun 2026 |
| Citadel Advisors Llc | 350K | 2.15% | +254.20% | Jun 2026 |
| CANTOR FITZGERALD, L. P. | 200K | 1.23% | 0.00% | Jun 2026 |
| MAVEN SECURITIES Ltd | 200K | 1.23% | 0.00% | Jun 2026 |
| Birchview Capital, LP | 120K | 0.74% | +140.00% | Jun 2026 |
| Two Sigma Investments LLC | 96.9K | 0.60% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 89.4K | 0.55% | -46.47% | Jun 2026 |
| XTX Topco Ltd | 71.7K | 0.44% | +13.59% | Jun 2026 |
| HRT FINANCIAL LLC | 62.7K | 0.39% | 0.00% | Jun 2026 |
| Susquehanna International Group, LLP | 49.6K | 0.30% | 0.00% | Jun 2026 |
| BlackRock Inc | 37.5K | 0.23% | 0.00% | Jun 2026 |
| KESTRA PRIVATE WEALTH SERVICES, LLC | 23.0K | 0.14% | +76.92% | Jun 2026 |
| UBS Group AG | 16.8K | 0.10% | -36.21% | Jun 2026 |
| Fundamentun, LLC | 11.2K | 0.07% | 0.00% | Jun 2026 |
| BNP Paribas Arbitrage, SA | 10.5K | 0.06% | +47.89% | Jun 2026 |
| Scientech Research LLC | 10.2K | 0.06% | 0.00% | Jun 2026 |
| Virtu Financial LLC | 10.2K | 0.06% | 0.00% | Jun 2026 |
Grace Therapeutics, Inc. company profile
- Company name
- Grace Therapeutics, Inc.
- Ticker
- GRCE.US
- Exchange
- USA Stocks
- Listed since
- Oct 8, 2024
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 5
- Fiscal year end
- March
- Address
- 103 Carnegie Center, Princeton, NJ, United States, 08540
- Phone
- 609 322 1602
- Website
- gracetx.com
About Grace Therapeutics, Inc.
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to enhance neurological symptoms of Ataxia-Telangiectasia (A-T); and GTX-101, a topical bio adhesive film-forming bupivacaine spray for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Grace Therapeutics, Inc. management
5- Mr. Prashant KohliCEO & Director · born 1972
- Mr. Amresh Kumar Ph.D.VP of Program Management · born 1980
- Ms. Carrie D'AndreaConsultant · born 1973
- Mr. Robert J. DelAversano CPAVP of Finance and Principal Financial & Accounting Officer · born 1972
- Dr. R. Loch MacDonald M.D., Ph.D.Member of Scientific Advisory Board & Chief Medical Officer · born 1962